Table 2.
Rates of positive UCV cases using (adapted) criteria of clinical atezolizumab, pembrolizumab and durvalumab trials.
| Table 2 | Atezolizumab criteria* | Pembrolizumab criteria* | Durvalumab criteria | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Histologic differentiation (n) | IC2/3 (SP263) (n, %) | IC2/3 (SP142) (n, %) | IC2/3 (22C3) (n, %) | TC+IC ≥10% (SP263) (n, %) | TC+IC ≥10% (SP142) (n, %) | TC+IC ≥10% (22C3) (n, %) | TC or IC ≥25% (SP263) (n, %) | TC or IC ≥25% (SP142) (n, %) | TC or IC ≥25% (22C3) (n, %) |
| Micropapillary (19) | 13 (68%) | 6 (32%) | 8 (42%) | 11 (58%) | 6 (32%) | 7 (37%) | 6 (32%) | 1 (5%) | 3 (16%) |
| Squamous differentiation (16) | 14 (88%) | 12 (75%) | 14 (88%) | 14 (88%) | 12 (75%) | 14 (88%) | 1 (6%) | 1 (6%) | 2 (13%) |
| Nested (14) | 8 (57%) | 3 (21%) | 4 (29%) | 5 (36%) | 2 (14%) | 3 (21%) | 4 (29%) | 1 (7%) | 2 (14%) |
| Plasmacytoid (14) | 12 (86%) | 3 (21%) | 7 (50%) | 7 (50%) | 1 (7%) | 2 (14%) | 2 (14%) | 0 (0%) | 0 (0%) |
| Small cell carcinoma (12) | 6 (50%) | 2 (17%) | 5 (42%) | 4 (33%) | 2 (17%) | 3 (25%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Glandular differentiation (9) | 8 (89%) | 5 (56%) | 8 (89%) | 7 (78%) | 2 (22%) | 4 (44%) | 2 (22%) | 2 (22%) | 1 (11%) |
| Total (84) | 61 (73%) | 31 (37%) | 46 (55%) | 48 (57%) | 25 (30%) | 33 (39%) | 15 (18%) | 5 (6%) | 8 (10%) |
IC2/3: immune cell reactivity in ≥5% of tumor-associated IC (*adapted IC score), TC+IC ≥10%: combined positive score as a sum of tumor cell and immune cell reactivity in ≥10% (*adapted positive score), TC or IC ≥25%: immunoreactivity in tumor cells or immune cells in ≥25%.